HYQVIA

Phase 3Biologic

HYQVIA is one of 65 biologic programs targeting Chronic Inflammatory Demyelinating Polyradiculoneuropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Inflammatory Demyelinating PolyradiculoneuropathyActive, not recruiting

Immunodeficiency DiseaseActive, not recruiting

NeuropathyActive, not recruiting

Chronic Inflammatory Demyelinating PolyradiculoneuropathyPhase 3

Active, not recruiting

Immunodeficiency DiseasePhase 2/Phase 3

Active, not recruiting

NeuropathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

114 competitors in Neuropathy

#DrugCompanyPhaseTrials

Asceniv

CSL Behring

Phase 3

1 2

Avandia

Alnylam Pharmaceuticals

Phase 3

1 3

Vimpat

UCB

Phase 3

1 4

Savella

AbbVie

Phase 3

1 5

Avicel

SSanthera Pharmaceuticals

Phase 3

3 6

Claritin

PPerrigo Company

Phase 3

1 7

Prilosec

DDexcel Pharma Technologies Ltd.

Phase 3

1 8

Glutamine

Sanofi

Phase 3

2 9

Curcumin

Merck & Co.

Phase 3

1 10

Taxol

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT06747351

Clinical

Trials by Indication[1]

Immunogenicity2 trials

Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects

Completed·BBaxalta now part of Shire·Phase 4·NCT03116347·42 enrolled

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

Completed·BBaxalta now part of Shire·Phase 3·NCT03277313·44 enrolled

Chronic Inflammatory Demyelinating Polyradiculoneuropathy2 trials

A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Recruiting· Takeda logo

Takeda·Phase 3·NCT06747351·59 enrolled

A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Completed·BBaxalta now part of Shire·Phase 3·NCT02549170·138 enrolled

Immunodeficiency Disease1 trial

A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases

Completed· Takeda logo

Takeda·Phase 2/3·NCT05755035·65 enrolled

Neuropathy1 trial

Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)

Completed·JJohannes Jakobsen·Phase 2·NCT02556437·18 enrolled

CIDP1 trial

Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

Completed·BBaxalta now part of Shire·Phase 3·NCT02955355·85 enrolled

6 more indications

Infusion1 trial

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Completed·BBaxalta now part of Shire·Phase 1·NCT04578535·51 enrolled

Outcome1 trial

Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO)

Completed·GGWT-TUD GmbH··NCT03054181·156 enrolled

Stiff-Person syndrome1 trial

Efficacy and Mechanism of Action of SCIg in Patients With Stiff Person Syndrome (SPS)

Unknown status·TThomas Jefferson University··NCT03829826·22 enrolled

Adult1 trial

A Study of TAK-881 and HyQvia in Healthy Adults

Completed· Takeda logo

Takeda·Phase 1·NCT06895967·30 enrolled

Pregnancy1 trial

Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia

Completed·BBaxalta now part of Shire··NCT02556775·16 enrolled

Unspecified1 trial

Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)

Completed·BBaxalta now part of Shire··NCT02593188·264 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for HYQVIA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HYQVIA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HYQVIA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Takeda

HYQVIA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Immunogenicity2 trials

Chronic Inflammatory Demyelinating Polyradiculoneuropathy2 trials

Immunodeficiency Disease1 trial

Neuropathy1 trial

CIDP1 trial

Infusion1 trial

Outcome1 trial

Stiff-Person syndrome1 trial

Adult1 trial

Pregnancy1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News